Evaluation of COVID-19 Vaccines Side Effects among Staff and Students of Misurata University in Libya

Saad Aboualkasem¹, Salem Ebraiek², Mohamed Elwash¹, Fatma Altahrouni¹, Fatima Alzarrouk¹

¹Department of Biotechnology, Faculty of Science, Misurata University, Libya
²Department of Epidemiology, Faculty of Health Science, Misurata University, Libya

*email: saad_libya@ymail.com

Article Info

Key word:
COVID-19 vaccination side effect Libya Misrata

ABSTRACT

After a year of COVID-19 being distributed in all countries worldwide, several COVID-19 vaccines were invented by different companies. All of these vaccines obtained emergency approval from WHO because of critical conditions to fight this pandemic, but still, scientists work on clinical experiments to approve the safety of these vaccines and their adverse effects. This research tried to check the safety of vaccines imported from the Libyan Health Ministry. The comparison was among Sinovak, Sinopharm, AstraZeneka, Sputnik V, and Pfizer- BioNTech vaccines. The research aimed to compare the side effects of each vaccine after 24 hours of vaccination, this information was collected from people who work or study at Misurata University. The first notice of survey results was the small number of people who took the second dose of all vaccines, even if all second doses have been provided by the health ministry with the exception of sputnik V. Most side effects were clear in sputnik V, AstraZeneka, and Pfizer- BioNTech, on the other hand, Sinopharm and Sinovac were mostly with little side effects although some people had headache and fever. This research recommends for more action forward campaign that aims to convince Libyan people to get COVID-19 vaccines.

Copyright © 2022 Author (s). All Right Reserved

Introduction

After the first reported case of COVID-19 in December 2019 in Wuhan, China, the pandemic was distributed around the world without exceptions. In Libya, the first case was reported on 24/3/2020, and cases took two months to start increasing remarkably (Gasibat, Raba, & Abobaker, 2020). After more than a year from the first case, the second wave of COVID-19 started to attack on July 2021, it was strong compared with the first wave (https://ncdc.org.ly/Ar/). Fortunately, the tough wave came when already a lot of invented vaccines have been approved (Gulati et al, 2020); Mao et al, 2021). Furthermore, some approved vaccines such as Sinovak and Oxford/AstraZeneka COVID-19 are already imported by the Libyan government, but with a small amount that targeted only hospitals staff and older people. The second move of the National Center for Disease Control in Libya (NCDC) to accelerate the vaccination inside the country was by contract with other companies who produce COVID-19 vaccines, by this step they could import other brands of vaccines such as Sputnik V, Sinopharm, and Pfizer-BioNTech's COVID-19 vaccine (Meo et al., 2021).
According to NCDC report which was published on 5/8/2021, Libya is still classified at the community spread stage. Where total cases reached 264,827 cases, and 3,659 death cases. Meanwhile, the recovered cases were 197,563 cases according to the new protocol that was approved by (NCDC). The conclusion of (NCDC) report mention that the country is experiencing enhancement of epidemiological situation, and advised the people to take the vaccine against COVID-19 (Abu-Hammad et al., 2021; Zhang et al., 2021).

To date, the number of people who were vaccinated with the first dose is 1,266,669 people and only 145,217 people received the second dose. These data were recorded on 15/9/2021 on the website of (NCDC) (Lazarus et al., 2021).

Even if the cases of infected people were decreased, the number of vaccinated people with a second dose is still low in the country with a population estimated at 6.8 million (Libya, Data, 2009). The low number is due to the delay in providing the second dose to vaccination centers as well as rumors spread in the community about the safety of the vaccines.

In this research, we tried to do a social survey to compare the adverse effects among COVID-19 vaccines that are used in Libya. The research was applied at Misurata University, in Misrata city in Libya. The survey targeted both students and university staff in the university. The questionnaire asked about what side effects they were experiencing after 24 hours of taking the vaccine, whether it was first or second dose. This research provides multiple choice of familiar side effects that reported for COVID-19 vaccines which were reported in previous studies (Djanas et al., 2021).

**Materials and Methods**

This research applied using a cross-sectional method to determine COVID-19 vaccines’ side effects among students and staff of Misurata University. The survey of this research was started on 1/9/2021 and the data was collected on 25/9/2021. The questionnaire was nameless and was distributed randomly on the campus, and it was consists of five closed-ended questions on age, gender, type of vaccine, if individuals suffering from any type of chronic disease, and side effects experienced after the first or second dose of the vaccine. The questionnaire is provided as a supplementary file.

**Results and Discussion**

**Results**

The survey data were collected from 238 students and university staff at Misurata University. The characteristics of the participants are presented in Table 1. Meanwhile, the side effects of the second dose of COVID-19 vaccines were shown in Table 2.

| Variable  | Dose 1 Recipients Total (238) | Dose 2 Recipients Total (15) | Both Doses Recipients % |
|-----------|-------------------------------|------------------------------|--------------------------|
| Gender    |                               |                              |                          |
| Male      | 116 (48.74%)                  | 9 (60%)                      | 7.76%                    |
| Female    | 122 (51.26%)                  | 6 (40%)                      | 4.92%                    |
| Age       |                               |                              |                          |
| 18 – 24   | 81 (34.03%)                   | 3 (20%)                      | 3.70%                    |
| 25 – 34   | 46 (19.33%)                   | 4 (26.67%)                   | 8.70%                    |
| 35 – 44   | 32 (13.45%)                   | 2 (13.33%)                   | 6.25%                    |
| 45 – 54   | 32 (13.45%)                   | 1 (6.67%)                    | 3.13%                    |
| 55 – 64   | 37 (15.55%)                   | 2 (13.33%)                   | 5.41%                    |
| 65 ≤      | 10 (4.20%)                    | 3 (20%)                      | 30%                      |
| Vaccine types |                           |                              |                          |
| Pfizer- BioNTech (PB) | 12 (5.04%)             | 3 (20%)                      | 25%                      |
| Oxford AstraZeneka (AZ) | 40 (16.80%)        | 9 (60%)                      | 22.5%                    |
| Sinopharm (Sp) | 28 (11.76%)          | -                            | -                        |
| Sinovac (Sv) | 21 (8.82%)                 | 1 (6.67%)                    | 4.76%                    |
| Sputnik V (Sn) | 137 (57.56%)             | 2 (13.33%)                   | 1.46%                    |

Table 1. Characteristics of the survey participants

http://jurnal.radenfatah.ac.id/index.php/biota
Figure 1. The percentages of each vaccine were collected from the survey. Oxford AstraZeneka (AZ), Sinopharm (Sp), Sinovac (Sv), Sputnik V (Sn), Pfizer-BioNTech (PB)

Discussion

Although, the second doses have been available, until the date of this research and according to the survey results, it was clear that most people did not take the opportunity to receive a second vaccine dose, which was clear that only 15 people had the second dose, even if the survey targeted high educated people. Although the number of people receiving each type of vaccine is dissimilar, the results were as expected compared with previous studies. Sputnik V and AstraZeneka caused the highest side effect (Babamahmoodi, Saeedi, & Navaei, 2021). On the other hand, Chinese vaccines (Sinovac and Sinopharm) showed the lowest side effects and showed no significant side effects. Still, Pfizer- BioNTech has moderate side effects (Table 2 and Figur 1).

Despite, the enormous variance of side effects of each vaccine, all vaccines share some familiar side effects such as fever and headache including the Sinovac vaccine. Although, there was a small number of individuals who receive the booster dose of vaccination, nevertheless the results showed no difference of side effects between first and second dose.

Obviously, there was no difference between males and females of side effect appearance, which means there is no relationship between gender of individuals and vaccines side effects (Soiza, Scicluna, & Thomson, 2021). Moreover, the side effect of vaccines for older individuals was not significantly different from those under 20 years old (Table 1). All side effects were moderate and acceptable, and we assumed that all vaccines are safe to use whatever the gender or age. Fortunately, the vaccine that has most side effects (Sputnik V) is no longer available in the vaccination center in Libya, and the government was directed to provide vaccination centers with Sinopharm and AstraZeneka, due to their efficacy and safety reports (Menni et al., 2021). Furthermore, until the date of collecting the research data, it is obvious that Libyan people still hesitate to receive the second dose of COVID-19 vaccines.

Table 2. Results of vaccines side effects

| Side effects       | Vaccine Types | Total (%)   |
|--------------------|---------------|-------------|
|                    | PB (%)  | AZ (%)  | Sp (%)  | Sv (%)  | Sn (%)  |              |
| Side effects       | 10 (83.34%)| 25 (62.50%)| 10 (35.71%)| 6 (28.57%)| 85 (62.04%)| 136 (57.14%)|
| No Side effects    | 02 (16.67%)| 15 (37.50%)| 18 (64.29%)| 15 (71.43%)| 52 (37.96%)| 102 (42.86%)|
| Hypersensitivity   |            |            |            |            |            |
| Yes                | 00 (00%)  | 00 (00%)  | 00 (00%)  | 00 (00%)  | 00 (00%)  | 00 (00%)    |
| No                 | 12 (100%) | 40 (100%) | 28 (100%) | 21 (100%) | 137 (100%)| 238 (100%)  |
| Side effects                        | PB (%)     | AZ (%)     | Sp (%)     | Sv (%)     | Sn (%)     | Total (%) |
|------------------------------------|------------|------------|------------|------------|------------|-----------|
| Non severe allergic reactions      |            |            |            |            |            |           |
| Yes                                | 00 (00%)   | 00 (00%)   | 00 (00%)   | 00 (00%)   | 00 (00%)   | 00 (00%)  |
| No                                 | 12 (100%)  | 40 (100%)  | 28 (100%)  | 21 (100%)  | 137 (100%) | 238 (100%)|
| Injection site pain                |            |            |            |            |            |           |
| Yes                                | 04 (33.33%)| 09 (29.03%)| 04 (14.28%)| 02 (9.52%) | 44 (32.11%)| 63 (26.47%)|
| No                                 | 08 (66.66%)| 31 (70.97%)| 24 (85.72%)| 19 (90.48%)| 93 (67.89%)| 175 (73.53%)|
| Injection site swelling            |            |            |            |            |            |           |
| Yes                                | 00 (00%)   | 01 (2.50%) | 00 (00%)   | 00 (00%)   | 19 (13.87%)| 20 (8.40%) |
| No                                 | 12 (100%)  | 39 (97.50%)| 28 (100%)  | 21 (100%)  | 118 (86.13%)| 218 (91.60%)|
| Headache                           |            |            |            |            |            |           |
| Yes                                | 05 (41.67%)| 09 (22.50%)| 05 (17.86%)| 03 (14.29%)| 55 (40.15%)| 77 (32.35%)|
| No                                 | 07 (58.33%)| 31 (77.50%)| 23 (82.14%)| 18 (85.71%)| 82 (69.85%)| 161 (67.65%)|
| Myalgia                            |            |            |            |            |            |           |
| Yes                                | 03 (25%)   | 07 (17.50%)| 01 (3.57%) | 00 (00%)   | 23 (16.79%)| 34 (14.29%)|
| No                                 | 09 (75%)   | 33 (82.50%)| 27 (96.43%)| 21 (100%)  | 114 (83.21%)| 204 (85.71%)|
| Chills                             |            |            |            |            |            |           |
| Yes                                | 00 (00%)   | 04 (10%)   | 00 (00%)   | 00 (00%)   | 13 (9.49%) | 17 (7.14%) |
| No                                 | 12 (100%)  | 36 (90%)   | 28 (100%)  | 21 (100%)  | 124 (90.51%)| 221 (92.86%)|
| Joint pain                         |            |            |            |            |            |           |
| Yes                                | 04 (33.33%)| 05 (12.50%)| 00 (00%)   | 00 (00%)   | 18 (13.14%)| 27 (11.34%)|
| No                                 | 08 (66.66%)| 35 (87.50%)| 28 (100%)  | 21 (100%)  | 119 (86.86%)| 211 (88.66%)|
| Vomiting                           |            |            |            |            |            |           |
| Yes                                | 00 (00%)   | 01 (2.50%) | 00 (00%)   | 00 (00%)   | 05 (3.65%) | 06 (2.52%) |
| No                                 | 12 (100%)  | 39 (97.50%)| 28 (100%)  | 21 (100%)  | 132 (96.35%)| 232 (97.48%)|
| Chest pain                         |            |            |            |            |            |           |
| Yes                                | 00 (00%)   | 02 (05%)   | 00 (00%)   | 00 (00%)   | 05 (3.65%) | 07 (2.94%) |
| No                                 | 12 (100%)  | 38 (95%)   | 28 (100%)  | 21 (100%)  | 132 (96.35%)| 231 (97.06%)|
| Palpitation                        |            |            |            |            |            |           |
| Yes                                | 00 (00%)   | 00 (00%)   | 02 (7.14%) | 00 (00%)   | 04 (2.92%) | 06 (2.52%) |
| No                                 | 12 (100%)  | 40 (100%)  | 26 (92.86%)| 21 (100%)  | 133 (97.08%)| 232 (97.48%)|
| Other Symptoms                     |            |            |            |            |            |           |
| Yes                                | 00 (00%)   | 01 (2.50%) | 00 (00%)   | 00 (00%)   | 03 (2.19%) | 4 (1.68%)  |
| No                                 | 12 (100%)  | 39 (97.50%)| 28 (100%)  | 21 (100%)  | 134 (97.81%)| 234 (98.32%)|
| Fatigue                            |            |            |            |            |            |           |
| Yes                                | 02 (16.67%)| 11 (27.50%)| 05 (17.86%)| 02 (9.52%) | 61 (44.53%)| 81 (34.03%)|
| No                                 | 10 (83.33%)| 29 (72.50%)| 23 (82.14%)| 19 (90.48%)| 76 (55.47%)| 157 (65.97%)|
| Fever                              |            |            |            |            |            |           |
| Yes                                | 04 (33.33%)| 05 (12.50%)| 04 (14.29%)| 02 (9.52%) | 49 (35.77%)| 64 (26.89%)|
| No                                 | 08 (66.66%)| 35 (87.50%)| 24 (85.71%)| 19 (90.48%)| 88 (64.23%)| 174 (73.11%)|
| Injection site Redness             |            |            |            |            |            |           |
| Yes                                | 00 (00%)   | 00 (00%)   | 01 (3.57%) | 00 (00%)   | 15 (10.95%)| 16 (6.72%) |
| No                                 | 12 (100%)  | 40 (100%)  | 27 (96.43%)| 21 (100%)  | 122 (89.05%)| 222 (93.28%)|
| Nausea                             |            |            |            |            |            |           |
| Yes                                | 00 (00%)   | 01 (2.50%) | 00 (00%)   | 00 (00%)   | 08 (5.84%) | 09 (03.78%)|
| No                                 | 12 (100%)  | 39 (97.50%)| 28 (100%)  | 21 (100%)  | 129 (94.16%)| 229 (96.22%)|
| Felling Unwell                     |            |            |            |            |            |           |
| Yes                                | 02 (16.67%)| 02 (05%)   | 03 (10.71%)| 00 (00%)   | 08 (5.84%) | 15 (6.30%) |
| No                                 | 10 (83.33%)| 38 (95%)   | 25 (89.29%)| 21 (100%)  | 129 (94.16%)| 223 (93.70%)|
| Lymphadenopathy                    |            |            |            |            |            |           |
| Yes                                | 00 (00%)   | 00 (00%)   | 00 (00%)   | 00 (00%)   | 01 (0.73%) | 01 (0.42%) |
| No                                 | 12 (100%)  | 40 (100%)  | 28 (100%)  | 21 (100%)  | 136 (99.27%)| 237 (99.58%)|

http://jurnal.radenfatah.ac.id/index.php/biota
Table 2. Continue

| Side effects | PB (%) | AZ (%) | Sp (%) | Sv (%) | Sn (%) | Total (%)
|--------------|--------|--------|--------|--------|--------|---------|
| Diarrhea     |        |        |        |        |        |         |
| Yes          | 00(00%)| 01(2.50%)| 01(3.57%)| 00(00%)| 06(4.38%)| 08(3.36%)|
| No           | 12(100%)| 39(97.50%)| 27(96.43%)| 21(100%)| 131(95.62%)| 220(96.64%)|
| Arm pain     |        |        |        |        |        |         |
| Yes          | 02(16.67%)| 05(12.50%)| 06(21.43%)| 02(9.52%)| 29(21.17%)| 44(18.49%)|
| No           | 10(83.33%)| 35(87.50%)| 22(78.57%)| 19(90.48%)| 108(78.83%)| 194(81.51%)|
| Shortness of breath |        |        |        |        |        |         |
| Yes          | 00(00%)| 01(2.50%)| 01(3.57%)| 00(00%)| 04(2.92%)| 06(2.52%)|
| No           | 12(100%)| 39(97.50%)| 27(96.43%)| 21(100%)| 133(97.08%)| 232(97.48%)|

Conclusion
The comparison was among Sinovak, Sinopharm, AstraZeneka, Sputnik V, and Pfizer-BioNTech vaccines, of the survey results was the small number of people who took the second dose of all vaccines, even if all second doses have been provided by the health ministry with the exception of sputnik V. Most side effects were clear in sputnik V, AstraZeneka, and Pfizer-BioNTech, on the other hand, Sinopharm and Sinovac were mostly with little side effects although some people had headache and fever.

References
Abu-Hammad, O., Alduraidi, H., Abu-Hammad, S., Alnazzawi, A., Babkair, H., Abu-Hammad, A., Dar-Odeh, N. (2021). Side effects reported by Jordanian healthcare workers who received covid-19 vaccines. Vaccines, 9(6), 1–10. https://doi.org/10.3390/vaccines9060577

Babamahmoodi, F., Saeedi, M., & Navaei, R. A. (2021). Side effects and immunogenicity following administration of the Sputnik V COVID - 19 vaccine in health care workers in Iran. Scientific Reports, 1–8. https://doi.org/10.1038/s41598-021-00963-7

Djanas, D., Yusirwan, Martini, R. D., Rahmadian, Putra, H., Zanir, A., … Nindrea, R. D. (2021). Survey data of COVID-19 vaccine side effects among hospital staff in a national referral hospital in Indonesia. Data in Brief, 36, 107098. https://doi.org/10.1016/j.dib.2021.107098

Gasibat, Q., Raba, A. A., & Abobaker, A. (2020). COVID-19 in Libya, fewer cases so far. Any speculations? Disaster Medicine and Public Health Preparedness, 1–2. https://doi.org/10.1017/dmp.2020.177

Gulati, A., Pomeranz, C., Qamar, Z., Thomas, S., Frisch, D., George, G., Summer, R., DeSimone, J., & Sundaram, B. (2020). A Comprehensive Review of Manifestations of Novel Coronaviruses in the Context of Deadly COVID-19 Global Pandemic. The American journal of the medical sciences, 360(1), 5–34. https://doi.org/10.1016/j.amjms.2020.05.006

Khan, T., Agnihotri, K., Tripathi, A., Mukherjee, S., Agnihotri, N., & Gupta, G. (2020). Covid-19: A worldwide, zoonotic, pandemic outbreak. Alternative Therapies in Health and Medicine, 26, 56–64.

Lai, C. C., Shih, T. P., Ko, W. C., Tang, H. J., & Hsueh, P. R. (2020). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. International journal of antimicrobial agents, 55(3), 105924. https://doi.org/10.1016/j.ijantimicag.20
Lazarus, J. V., Ratzan, S. C., Palayew, A., Gostin, L. O., Larson, H. J., Rabin, K., Kimball, S., & El-Mohandes, A. (2021). A global survey of potential acceptance of a COVID-19 vaccine. Nature medicine, 27(2), 225–228. https://doi.org/10.1038/s41591-020-1124-9

Libya, Data. (n.d.). 2009, from https://data.worldbank.org/country/libya. Retrieved September 16

Lin, Y., Hu, Z., Zhao, Q., Alias, H., Danaee, M., & Wong, L. P. (2020). Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China. PLoS neglected tropical diseases, 14(12), e0008961. https://doi.org/10.1371/journal.pntd.0008961

Menni, C., Klaser, K., May, A., Polidori, L., Capdevila, J., Louca, P., … Spector, T. D. (2021). Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. The Lancet Infectious Diseases, 21(7), 939–949. https://doi.org/10.1016/S1473-3099(21)00224-3

Meo, S. A., Alhowikan, A. M., Al-Khlaiwi, T., Meo, I. M., Halepoto, D. M., Iqbal, M., Usmani, A. M., Hajjar, W., & Ahmed, N. (2020). Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. European review for medical and pharmacological sciences, 24(4), 2012–2019. https://doi.org/10.26355/eurrev_202002_20379

Meo, S. A., Bukhari, I. A., Akram, J., Meo, A. S., & Klonoff, D. C. (2021). COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. European review for medical and pharmacological sciences, 25(3), 1663–1669. https://doi.org/10.26355/eurrev_202102_24877

Self, W. H., Tenforde, M. W., Rhoads, J. P., Gaglani, M., Ginde, A. A., Douin, D. J., Olson, S. M., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., McNeal, T., Ghamande, S., Gibbs, K. W., Files, D. C., Hager, D. N., Shehu, A., Prekker, M. E., Erickson, H. L., Gong, M. N., … IVY Network (2021). Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021. MMWR. Morbidity and mortality weekly report, 70(38), 1337–1343. https://doi.org/10.15585/mmwr.mm7038e1

Soiza, R. L., Scicluna, C., & Thomson, E. C. (2021). Efficacy and safety of COVID-19 vaccines in older people. Age and Ageing, 50(2), 279–283. https://doi.org/10.1093/ageing/afaa274

Tenforde, M. W., Self, W. H., Naioti, E. A., Ginde, A. A., Douin, D. J., Olson, S. M., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., Gaglani, M., McNeal, T., Ghamande, S., Shapiro, N. I., Gibbs, K. W., Files, D. C., Hager, D. N., Shehu, A., Prekker, M. E., Erickson, H. L., … IVY Network (2021). Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021. MMWR. Morbidity and mortality weekly report, 70(34), 1156–1162. https://doi.org/10.15585/mmwr.mm7034e2

Xing, K., Tu, X. Y., Liu, M., Liang, Z. W., Chen, J. N., Li, J. J., Jiang, L. G., Xing, F. Q., & Jiang, Y. (2021). Efficacy and safety of COVID-19 vaccines: a systematic review. Zhongguo dang dai...
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet. Infectious diseases, 21(2), 181–192. https://doi.org/10.1016/S1473-3099(20)30843-4

Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., Chen, X., Hu, Y., Liu, X., Jiang, C., Li, J., Yang, M., Song, Y., Wang, X., Gao, Q., & Zhu, F. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–22 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet. https://doi.org/10.7499/j.issn.1008-8830.2101133

er ke za zhi = Chinese journal of contemporary pediatrics, 23(3), 221–228.